Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer modelsRachel M. Squillace(Ariadne Diagnostics (United States)), Victor M. Rivera(Ariadne Diagnostics (United States))International Journal of OncologyMay 18, 201210.3892/ijo.2012.1487Cited by 31SaveCiteExport RISWatch citationsRelated PapersThe Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models|Clinical Cancer Research|2016|325Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models|Unknown|2023|0